<DOC>
	<DOC>NCT00072852</DOC>
	<brief_summary>The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.</brief_summary>
	<brief_title>Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Women with diagnosis of primary adenocarcinoma of the breast Presence of locally advanced or metastatic disease nonamenable to surgery or radiation therapy with curative intent At least one measurable lesion &gt;20mm (or &gt;10 mm with spiral CT scan) Must have received (and failed) prior treatment with an anthracycline, a taxane, and capecitabine in the adjuvant and/or advanced disease treatment setting Women at least 18 years old, with performance status 02 Prior treatment with another topoisomerase I inhibitor Current enrollment in another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>